0L8.F Lantheus Holdings Inc

Healthcare Pharmaceuticals Frankfurt Exchange
90.30 EUR
Close of Nov 12, 2026
44.41 96.80
Market cap
EUR 5.91B
P/E
26.4x
P/B
4.83x
ROE
21.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 0L8.F undervalued?

Graham number
Price90.30
Graham value37.91
Premium138.2%

0L8.F trades 138.2% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Lantheus Holdings Inc fundamental analysis

No fundamental analysis for Lantheus Holdings Inc yet.

Lantheus Holdings Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Lantheus Holdings Inc

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to…

Full company profile